...
首页> 外文期刊>Infection and immunity >Functional Activity of Anti-Neisserial Surface Protein A Monoclonal Antibodies against Strains of Neisseria meningitidis Serogroup B
【24h】

Functional Activity of Anti-Neisserial Surface Protein A Monoclonal Antibodies against Strains of Neisseria meningitidis Serogroup B

机译:抗脑膜炎奈瑟氏球菌血清群B株抗奈瑟氏表面蛋白A单克隆抗体的功能活性

获取原文
           

摘要

Neisserial surface protein A (NspA) is currently being investigated with humans as a candidate vaccine for the prevention of meningococcal disease. Although NspA is highly conserved, the ability of anti-NspA antibodies to bind to or elicit complement-mediated bactericidal activity against diverse Neisseria meningitidis serogroup B strains is controversial. To evaluate strain differences in NspA surface accessibility and susceptibility to bactericidal activity, we prepared murine immunoglobulin G2a anti-NspA monoclonal antibodies (MAbs) and evaluated their functional activity against 10 genetically diverse N. meningitidis serogroup B strains. By colony Western blot, all 10 strains expressed NspA as detected by one or more MAbs. By flow cytometry, two MAbs were found to bind to the bacterial surface of 6 of the 10 strains. In addition, two strains showed variable NspA surface accessibility for the MAbs despite being uniformly positive for NspA expression by colony Western blotting. Only 4 of the 10 strains were susceptible to anti-NspA complement-mediated bacteriolysis. Passively administered MAb protected infant rats from developing bacteremia after challenge with N. meningitidisserogroup B strain 8047 (surface binding positive, susceptible to anti-NspA bacteriolysis), was poorly protective against strain BZ232 (surface binding variable, resistant to bacteriolysis), and did not protect against strain M986 (surface binding negative, resistant to bacteriolysis). Finally, NspA does not appear to be critical for causing bacteremia, as an NspA knockout from strain 8047 was highly virulent in infant rats. Taken together, these findings suggest that an NspA-based vaccine will need to incorporate additional antigens to elicit broad protection against N. meningitidis serogroup B.
机译:目前正在与人一起研究奈瑟球表面蛋白A(NspA)作为预防脑膜炎球菌疾病的候选疫苗。尽管NspA是高度保守的,但抗NspA抗体结合或引发补体介导的针对各种B型脑膜炎奈瑟氏球菌血清菌株的杀菌活性的能力仍存在争议。为了评估菌株在NspA表面可及性和对杀菌活性的敏感性方面的差异,我们制备了鼠免疫球蛋白G2a抗NspA单克隆抗体(MAbs),并评估了它们对10种遗传多样的 N的功能活性。脑膜炎B血清群菌株。通过菌落Western印迹,如通过一种或多种MAb所检测,所有10个菌株均表达NspA。通过流式细胞术,发现两个MAb结合至10个菌株中的6个的细菌表面。另外,尽管通过菌落Western印迹对NspA表达一致阳性,但两种菌株对MAb显示出可变的NspA表面可及性。 10个菌株中只有4个对抗NspA补体介导的溶菌作用敏感。被动施用的单克隆抗体可保护婴儿免受Nem攻击后产生菌血症。脑膜炎双球菌血清群B菌株8047(表面结合阳性,易受NspA的细菌分解作用),对BZ232菌株(表面结合可变,对细菌分解的抵抗力)的保护作用较差,对M986菌株(表面结合阴性,耐细菌分解)。最后,NspA似乎对引起菌血症不是至关重要的,因为从8047株中分离出NspA对幼鼠具有高毒性。综上所述,这些发现表明,基于NspA的疫苗将需要掺入其他抗原,以引发针对 N的广泛保护。脑膜炎B血清群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号